Cannabinoid/opioid crosstalk in the central nervous system.
Promising therapeutic uses and a great variety of pharmacological effects are the leading forces that focus actual cannabinoid research. Cannabinoid and opioid systems share neuroanatomical, neurochemical, and paharmacological features. This fact supports the notion that actions induced by each one of these types of drugs involved an interaction between the endogenous opioid and endocannabinoid neuronal systems. Over the last decade our group and others have investigated cannabinoid/opioid crosstalk in the central nervous system by studying the mechanisms underlying pharmacological and biochemical interactions between the two systems in experimental paradigms of antinociception, drug reinforcement, and anxiety. The goal of this review is to revise the latest work done on this subject, with special emphasis on the research done with genetically modified animals. Whereas clinical progress is going ahead slowly, basic research in this area is progressing rapidly. Clinical applications derived from the cannabinoid/opioid crosstalk and based tightly on medical evidence are yet to come, but it is hoped that knowledge of this central messenger interaction will help to develop new alternatives for the treatment of some pathological states.
Corchero
Javier
J
Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias, Universidad de Extremadura, Badajoz, Spain.
Manzanares
Jorge
J
Fuentes
José A
JA
D000818:Animals; D001007:Anxiety / Q000503:physiopathology / Q000523:psychology; D063386:Cannabinoid Receptor Agonists; D002186:Cannabinoids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D009294:Narcotics / Q000494:pharmacology* / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D010147:Pain Measurement / Q000187:drug effects; D020239:Receptor Cross-Talk / Q000187:drug effects*; D043882:Receptors, Cannabinoid / Q000187:drug effects*; D011957:Receptors, Opioid / Q000819:agonists / Q000187:drug effects*; D019966:Substance-Related Disorders / Q000503:physiopathology
D063386:Cannabinoid Receptor Agonists; D002186:Cannabinoids; D009294:Narcotics; D043882:Receptors, Cannabinoid; D011957:Receptors, Opioid